Phase 3 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 50 years of age or older at the time you give consent
- You have been diagnosed with a specific type of wet age-related macular degeneration (wet AMD) that has caused abnormal blood vessel growth in your eye, and you have either never received eye injections for this condition, or you have had no more than 4 eye injections and were diagnosed no more than 6 months before the screening visit
- The abnormal blood vessels in your eye are currently active and causing fluid or leakage, as confirmed by eye imaging tests at your screening visit
- Your eye has shown a positive response to a specific eye injection medication called aflibercept, as confirmed by an independent review center
- Your vision in the study eye falls within a specific range — roughly between 20/320 and 20/32 on a standard eye chart — at the screening visit
- The thickness of the central part of your retina is at or below a certain measurement (500 microns) at the screening visit, as confirmed by an independent review center
Who may not be able to join:
- The abnormal blood vessel growth in your eye is caused by something other than wet AMD, or there is scarring, tissue loss, or significant bleeding in the central part of your retina
- You have a history of a detached retina in the study eye
- You have a history of or currently have active inflammation in either eye
- You have glaucoma or high pressure in your eye that requires more than 2 eye drop medications to control
- You have had any previous or ongoing treatments for the abnormal blood vessels or certain eye structure problems in the study eye, other than the allowed eye injections mentioned above
- You have had a major illness or major surgery in the 28 days before your screening visit
- You have uncontrolled high blood pressure
- You have had a heart attack, certain heart procedures, stroke, or a mini-stroke within 6 months of the screening visit
- You have a history of an autoimmune condition that could increase the risk of eye inflammation (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Julie Tsai, MD, 4D Molecular Therapeutics
Phone: (888) 748-8881
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Mean change from baseline in Best Corrected Visual Accuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.